Nimble Technologies

Nimble Therapeutics is a biotechnology company specializing in the discovery and development of novel peptide therapeutics. Spun out of Roche in 2019, the company utilizes a proprietary high-density DNA microarray-based platform to synthesize and screen millions of peptides simultaneously. This technology allows for the rapid optimization of macrocyclic and linear peptides with improved medicinal chemistry properties. Nimble operates primarily through strategic partnerships with major pharmaceutical companies, including Roche, Genentech, and Incyte, to advance programs in oncology, immunology, and metabolic diseases. The company's platform is particularly effective at identifying ligands for difficult-to-drug targets. By integrating chemical synthesis with high-throughput screening, Nimble significantly accelerates the lead identification process for its partners.